Paciullo, Francesco
,
Proietti, Marco
Bianconi, Vanessa http://orcid.org/0000-0001-6987-9349
Nobili, Alessandro
Pirro, Matteo
Mannucci, Pier Mannuccio
Lip, Gregory Y. H.
Lupattelli, Graziana
Funding for this research was provided by:
Italian Society of Internal Medicine
Ca’ Granda Maggiore Policlinico Hospital Foundation
Mario Negri Institute of Pharmacological Research
Pfizer
Article History
First Online: 21 March 2018
Compliance with ethical standards
:
: The REPOSI study was supported by the Italian Society of Internal Medicine (SIMI), the Ca’ Granda Maggiore Policlinico Hospital Foundation, and the Mario Negri Institute of Pharmacological Research. This study was supported by an unrestricted grand from Pfizer to the Scientific Director of Ca’ Granda Maggiore Policlinico Hospital Foundation.
: Marco Proietti has received a consulting fee from Boehringer Ingelheim. Pier Mannuccio Mannucci has received honoraria for lectures as speaker or chair symposia organized by Bayer, Grifols, Kedrion, LFB, Novo Nordisk and Pfizer, and is a scientific consultant for Bayer, Baxalta and Kedrion. Gregory Y.H. Lip is a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo, and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. All other authors have no conflicts of interest to disclose.